Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Placebo Controlled, Multicenter Study to Investigate the Safety and Efficacy of ATH008 Cream in Patients With Palmar-Plantar Erythrodysesthesia Syndrome (PPES) Secondary to Capecitabine Therapy.

NCT01316406 is registered in ClinicalTrials.gov with Advancell - Advanced In Vitro Cell Technologies, S.A. as lead sponsor.

NCT NCT01316406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01316406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Placebo Controlled, Multicenter Study to Investigate the Safety and Efficacy of ATH008 Cream in Patients With Palmar-Plantar Erythrodysesthesia Syndrome (PPES) Secondary to Capecitabine Therapy.
Lead sponsor
Advancell - Advanced In Vitro Cell Technologies, S.A.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
August 31, 2013
Enrollment
122 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

palmar-plantar erythrodysesthesia syndrome